Treatment-Resistant Depression
39
11
11
14
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.3%
4 terminated out of 39 trials
77.8%
-8.7% vs benchmark
10%
4 trials in Phase 3/4
50%
7 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (39)
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression
Stereotactic Radiotherapy Treatment for Treatment-resistant Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression
Olfactory and Brain Stimulations in Treatment-resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
A Trial of GH001 in Patients With Treatment-resistant Depression
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
Physical Activity Program for TRD
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Does Psilocybin Require Psychedelic Effects to Treat Depression?
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)